Insulin and Injectable Therapy:
Posters and Abstracts from San Diego

Source: American Diabetes Association 77th Scientific Sessions held June 9-13, 2017

Mayer Davidson, MD, and Vivian Fonseca, MD, provide their perspectives on the clinical importance of 10 posters presented at the 77th Scientific Sessions of the American Diabetes Association from June 9-13, 2017. Drs. Davidson and Fonseca summarize the latest research developments on key mechanisms in the pathogenesis of type 2 diabetes mellitus and how they are modified by basal and prandial insulins and glucagon-like peptide-1 receptor agonists. In addition, Drs. Davidson and Fonseca provide their insight into the clinical implications of clinical trial results regarding the efficacy, safety, and tolerability of recently available and investigational injectable medications for diabetes mellitus.

Proceed at your own pace and in any order. Each study perspective is about 5 minutes.

Enter your information to begin.
Downloadable Activity Resources

Content Areas

  • Basal insulins- degludec and glargine U-300
  • Prandial insulins- faster aspart, ultra-rapid lispro, follow-on lispro
  • Glucagon-like peptide-1 receptor agonists- dulaglutide, exenatide, lixisenatide, semaglutide
  • Glucagon-like peptide-1 receptor agonist via implantable mini-pump
  • Fixed-ratio basal insulin/glucagon-like peptide-1 receptor agonist

Faculty

Mayer Davidson, MD
Mayer Davidson, MD
Professor of Medicine
Charles R. Drew University
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Vivian Fonseca, MD
Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Tullis-Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana
CME Credit
Available Credit: 2.50 AMA PRA Category 1 Credits™.
2.50 ANCC Contact Hours
Opens: July 31, 2017
Expires: July 30, 2018
Target Audience: Endocrinologists
Primary Care Physicians
Physician Assistants
Nurse Practioners
Nurses
Other Health Care Providers
Supported by an educational grant from Novo Nordisk Inc.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.